MedTrace Logo

Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED)

NCT00420810 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2015-01-14

No results posted yet for this study

Summary

The purpose of this study is determine whether this drug will improve your insomnia in terms of decreasing your time to fall asleep and allowing you to stay asleep longer. The drug will be compared against placebo in order to determine if there's a difference.

Conditions

  • Primary Insomnia

Interventions

DRUG

MK0928 / Duration of Treatment : 8 Weeks

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2007-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00420810 on ClinicalTrials.gov